<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Precision Oncology on FinanClub</title>
    <link>https://finan.club/tags/precision-oncology/</link>
    <description>Recent content in Precision Oncology on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 26 Feb 2024 09:04:57 +0000</lastBuildDate><atom:link href="https://finan.club/tags/precision-oncology/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>GH</title>
      <link>https://finan.club/us/gh/</link>
      <pubDate>Mon, 26 Feb 2024 09:04:57 +0000</pubDate>
      
      <guid>https://finan.club/us/gh/</guid>
      <description>score:175
Chances: GH anticipates continued expansion with 2024 revenue outlook set between $655 to $670 million. The average of price targets set by Wall Street analysts indicates a potential upside of 109.9% in Guardant Health (GH). Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.</description>
    </item>
    
  </channel>
</rss>
